All Photos(1)

Documents

COO/COA

1134299

USP

Citalopram Related Compound F

Name: Citalopram Related Compound F
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(RS)-Dimethyl(1-methyl-3,3-diphenylallyl)amine hydrochloride

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₈H₂₁N · HCl

CAS Number:

55011-89-7

Molecular Weight:

287.83

UNSPSC Code:

41116107

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

citalopram

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C18H21N.ClH/c1-15(19(2)3)14-18(16-10-6-4-7-11-16)17-12-8-5-9-13-17;/h4-15H,1-3H3;1H

InChI key

ZVTAYVQUGPGRAF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Citalopram Related Compound F USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Citalopram Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1134233

Citalopram hydrobromide, United States Pharmacopeia (USP) Reference Standard

1134244

1134222

1134197

1134288

1134266

1134255

1134277

PHR1906

PHR1902

PHR1904

PHR1903

BP1153

Citalopram hydrobromide, British Pharmacopoeia (BP) Reference Standard

PHR1905

PHR1901

BP1154

Citalopram impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictograms

GHS06

Signal Word

Danger

Hazard Statements

H301

Precautionary Statements

P301 + P310

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.

M Kjaer et al.

Acta oncologica (Stockholm, Sweden), 27(5), 583-589 (1988-01-01)

Thirteen cancer patients with moderate to severe chronic pain of malignant origin on treatment with Ketogan tablets were included in an open non-randomized cross-over study comparing the analgesic effect, side effects and serum concentrations of Ketogan tablets and mixture. The

Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist.

B Ebert et al.

Pharmacology & toxicology, 82(3), 157-160 (1998-04-29)

The opioid, ketobemidone, has previously been shown to be a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In Denmark, ketobemidone is available in a formulation which contains ketobemidone and a spasmolytic compound, (RS)-3-dimethylamino-1,1-diphenylbut-1-ene, hydrochloride (A29), in a one to five ratio. Using

Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.

N Grosman

Acta pharmacologica et toxicologica, 50(1), 78-80 (1982-01-01)

Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine.

J C Raeder et al.

Acta anaesthesiologica Scandinavica, 30(7), 502-506 (1986-10-01)

A double-blind comparison of the effect of Ketogan (ketobemidone and A-29, an anticholinergic and spasmolytic agent) and morphine + scopolamine as premedication was performed in 113 women admitted for abortion and in 114 women admitted for gynaecological dilatation and curettage.

Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.

P Anderson et al.

European journal of clinical pharmacology, 19(3), 217-223 (1981-02-01)

The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery. Plasma concentrations were measured following intravenous administration of Ketogin 2 ml, containing ketobemidone chloride 10 mg, and a spasmolytic compound N,N-dimethyl-3,3-diphenyl-1-methylallylamine

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service